LT3182975T - Tabletės su didele rukaparibo doze - Google Patents

Tabletės su didele rukaparibo doze

Info

Publication number
LT3182975T
LT3182975T LTEPPCT/US2015/045522T LTUS2015045522T LT3182975T LT 3182975 T LT3182975 T LT 3182975T LT US2015045522 T LTUS2015045522 T LT US2015045522T LT 3182975 T LT3182975 T LT 3182975T
Authority
LT
Lithuania
Prior art keywords
rucaparib
tablets
dose
rucaparib tablets
dose rucaparib
Prior art date
Application number
LTEPPCT/US2015/045522T
Other languages
English (en)
Lithuanian (lt)
Inventor
Jeffrey Etter
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of LT3182975T publication Critical patent/LT3182975T/lt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2009Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
LTEPPCT/US2015/045522T 2014-08-22 2015-08-17 Tabletės su didele rukaparibo doze LT3182975T (lt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462040849P 2014-08-22 2014-08-22
US201562101739P 2015-01-09 2015-01-09
PCT/US2015/045522 WO2016028689A1 (en) 2014-08-22 2015-08-17 High dosage strength tablets of rucaparib

Publications (1)

Publication Number Publication Date
LT3182975T true LT3182975T (lt) 2025-11-25

Family

ID=55347324

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEPPCT/US2015/045522T LT3182975T (lt) 2014-08-22 2015-08-17 Tabletės su didele rukaparibo doze

Country Status (24)

Country Link
US (3) US9987285B2 (enExample)
EP (1) EP3182975B1 (enExample)
JP (3) JP6574477B2 (enExample)
KR (2) KR102803917B1 (enExample)
CN (2) CN106794185A (enExample)
AU (2) AU2015305696B2 (enExample)
BR (1) BR112017000865A2 (enExample)
CA (1) CA2955495C (enExample)
DK (1) DK3182975T3 (enExample)
ES (1) ES3048688T3 (enExample)
FI (1) FI3182975T3 (enExample)
HR (1) HRP20251484T1 (enExample)
IL (1) IL249946B (enExample)
LT (1) LT3182975T (enExample)
MX (1) MX367260B (enExample)
NZ (1) NZ728392A (enExample)
PL (1) PL3182975T3 (enExample)
PT (1) PT3182975T (enExample)
RS (1) RS67356B1 (enExample)
RU (1) RU2705156C2 (enExample)
SG (1) SG11201700265VA (enExample)
SI (1) SI3182975T1 (enExample)
SM (1) SMT202600141T1 (enExample)
WO (1) WO2016028689A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3102564A4 (en) 2014-02-05 2017-10-18 Merck Sharp & Dohme Corp. Tablet formulation for cgrp-active compounds
US12168004B2 (en) 2014-02-05 2024-12-17 Merck Sharp & Dohme Llc Treatment of migraine
AU2015305696B2 (en) * 2014-08-22 2019-08-29 Pharma& Schweiz Gmbh High dosage strength tablets of rucaparib
CN106008530B (zh) * 2016-07-24 2018-06-26 石家庄久正生物科技有限公司 一种抗卵巢癌药物Rucaparib关键中间体的制备方法
CN108201534A (zh) * 2016-12-16 2018-06-26 苏州苏融生物医药有限公司 一种瑞卡帕布口服缓控释药物组合物及其用途
EP3573990B1 (en) 2017-01-24 2024-07-10 Assia Chemical Industries Ltd. Solid state forms of rucaparib and of rucaparib salts
EA201992177A1 (ru) 2017-03-27 2020-02-25 Тесаро, Инк. Композиции на основе нирапариба
AU2018341479B2 (en) * 2017-09-26 2022-02-17 Tesaro, Inc. Niraparib formulations
WO2019130229A1 (en) 2017-12-28 2019-07-04 Mylan Laboratories Ltd Methods and intermediates for preparing rucaparib
CN111989137A (zh) 2018-01-05 2020-11-24 赛博克萨1公司 用于治疗涉及酸性或缺氧性患病组织的疾病的化合物、组合物和方法
US12383545B1 (en) 2018-06-08 2025-08-12 Allergan Pharmaceuticals International Limited Treatment of migraine
CN109111454A (zh) * 2018-08-01 2019-01-01 宁波金未生物科技有限公司 一种瑞卡帕布s-樟脑磺酸盐
CN108853030B (zh) * 2018-09-26 2021-10-01 上海朝晖药业有限公司 一种治疗恶性肿瘤的药物制剂及其制备方法
WO2020113500A1 (zh) * 2018-12-06 2020-06-11 上海诚妙医药科技有限公司 芦卡帕利樟脑磺酸盐的新晶型和制备方法及其用途
KR20220052918A (ko) 2019-07-10 2022-04-28 싸이브렉사 2, 인크. 치료제로서의 사이토톡신의 펩티드 접합체
PH12022550037A1 (en) 2019-07-10 2023-04-12 Cybrexa 3 Inc Peptide conjugates of microtubule-targeting agents as therapeutics
ES3014370T3 (en) 2020-04-28 2025-04-22 Rhizen Pharmaceuticals Ag Novel compounds useful as poly(adp-ribose) polymerase (parp) inhibitors
ES3051838T3 (en) 2020-07-14 2025-12-30 Assia Chem Ind Ltd Solid state forms of rucaparib salts
EP4188375A4 (en) 2020-07-29 2024-07-24 Allergan Pharmaceuticals International Limited MIGRAINE TREATMENT
WO2022090938A1 (en) 2020-10-31 2022-05-05 Rhizen Pharmaceuticals Ag Phthalazinone derivatives useful as parp inhibitors
AU2021409718A1 (en) 2020-12-22 2023-07-13 Allergan Pharmaceuticals International Limited Treatment of migraine
TW202304447A (zh) 2021-04-08 2023-02-01 瑞士商瑞森製藥公司 聚(adp-核糖)聚合酶抑制劑
MX2024003952A (es) 2021-09-27 2024-05-27 Allergan Pharmaceuticals Int Ltd Combinación que comprende atogepant para tratar la migraña.
JP2024543323A (ja) * 2021-11-10 2024-11-21 クリチテック,インコーポレイテッド ルカパリブ粒子およびその使用
EP4463232A1 (en) 2022-01-11 2024-11-20 Assia Chemical Industries Ltd. Solid state forms of rucaparib tosylate

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EE05006B1 (et) 1999-01-11 2008-04-15 Agouron Pharmaceuticals, Inc. Polü(ADP-riboos)polümeraaside tritsüklilised inhibiitorid ja neid sisaldavad farmatseutilised kompositsioonid
JP2006522088A (ja) 2003-03-31 2006-09-28 ファイザー・インク ポリ(adp−リボース)ポリメラーゼの三環系阻害剤の塩
PL1660095T3 (pl) 2003-07-25 2010-07-30 Cancer Research Tech Ltd Tricykliczne inhibitory PARP
PL1794163T3 (pl) 2004-09-22 2010-06-30 Pfizer Sposób wytwarzania inhibitorów poli(adp-rybozo)polimerazy
ATE551345T1 (de) 2004-09-22 2012-04-15 Pfizer Polymorphe formen des phosphatsalzes von 8-fluor- 2-ä4-ä(methylamino)methylüphenylü-1,3,4,5- tetrahydro-6h-azepinoä5,4,3-cdüindol-6-on
JP2008513435A (ja) 2004-09-22 2008-05-01 ファイザー・インク ポリ(adp−リボース)ポリメラーゼ阻害剤を含む治療用組成物
JP2011516527A (ja) * 2008-04-09 2011-05-26 レツク・フアーマシユーテイカルズ・デー・デー 医薬品有効成分の造粒
DK3150610T3 (da) * 2010-02-12 2019-11-04 Pfizer Salte og polymorfer af 8-fluor-2-{4-[(methylamino}methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-on
US20140044802A1 (en) * 2012-04-05 2014-02-13 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase and combination therapies thereof
AU2015305696B2 (en) 2014-08-22 2019-08-29 Pharma& Schweiz Gmbh High dosage strength tablets of rucaparib

Also Published As

Publication number Publication date
HRP20251484T1 (hr) 2026-01-02
PT3182975T (pt) 2025-10-28
US20180200260A1 (en) 2018-07-19
IL249946A0 (en) 2017-03-30
US10130636B2 (en) 2018-11-20
ES3048688T3 (en) 2025-12-11
RU2017109139A (ru) 2018-09-24
MX367260B (es) 2019-08-12
US20160051561A1 (en) 2016-02-25
RU2705156C2 (ru) 2019-11-05
AU2019272064A1 (en) 2019-12-19
MX2017001540A (es) 2017-05-11
KR20170043597A (ko) 2017-04-21
WO2016028689A1 (en) 2016-02-25
EP3182975A1 (en) 2017-06-28
JP2017525712A (ja) 2017-09-07
BR112017000865A2 (pt) 2017-12-05
FI3182975T3 (fi) 2025-11-13
JP6797980B2 (ja) 2020-12-09
AU2015305696A1 (en) 2017-02-02
AU2015305696B2 (en) 2019-08-29
SMT202600141T1 (it) 2026-05-12
CA2955495A1 (en) 2016-02-25
SG11201700265VA (en) 2017-02-27
KR102803917B1 (ko) 2025-05-07
JP7127101B2 (ja) 2022-08-29
JP6574477B2 (ja) 2019-09-11
NZ728392A (en) 2023-06-30
CA2955495C (en) 2023-09-19
RS67356B1 (sr) 2025-11-28
RU2017109139A3 (enExample) 2019-03-06
SI3182975T1 (sl) 2025-12-31
CN106794185A (zh) 2017-05-31
US9987285B2 (en) 2018-06-05
DK3182975T3 (da) 2025-10-20
IL249946B (en) 2020-05-31
KR20230097211A (ko) 2023-06-30
US20190099430A1 (en) 2019-04-04
JP2020002149A (ja) 2020-01-09
PL3182975T3 (pl) 2026-02-23
EP3182975A4 (en) 2018-04-18
AU2019272064B2 (en) 2021-11-18
JP2021038242A (ja) 2021-03-11
EP3182975B1 (en) 2025-10-01
CN113209033A (zh) 2021-08-06

Similar Documents

Publication Publication Date Title
SI3182975T1 (sl) Visokoodmerne tablete rukapariba
DK3175132T3 (da) Befæstelseselementer
IL254818A0 (en) Ribociclib tablet
DK3160978T3 (da) Gemcitabin-prodrugs
DK3110442T3 (da) Modificerede meningokok-fhbp-polypeptider
LT3183340T (lt) Termolabilios egzonukleazės
DK3189891T3 (da) Kombinationstabletmaskine
UA31197S (uk) Таблетка
EP4546794C0 (en) AUDIO CONNECTION CONCEPT
BR112016026078A2 (pt) Produto absorvente
KR20180084810A (ko) 정제 세트
LT3169854T (lt) Klozeto mazgas
DK2987556T3 (da) Knuseværk
DE112015004618A5 (de) Garnitur
TH1401006763B (th) เครื่องหั่น
TH1401006762B (th) เครื่องหั่น
TH1601003376A (th) ผลิตภัณฑ์ดูดซับ
TH1601002833B (th) ผลิตภัณฑ์ดูดชับ
TH1601001888A (th) ผลิตภัณฑ์ซึมซับ
TH1601003049A (th) ผลิตภัณฑ์ซึมซับ
TH1601000408A (th) ผลิตภัณฑ์ดูดซับ
TH1501007352B (th) ผลิตภัณฑ์ซึมซับ
TH1501007129B (th) ผลิตภัณฑ์ซึมซับ
TH1601006627A (th) ผลิตภัณฑ์ซึมซับ
TH1501007868A (th) ผลิตภัณฑ์ดูดซับ